Jonas Cicenas
Overview
Explore the profile of Jonas Cicenas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cicenas J, Simkus J
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672637
The protein kinases are a large family of enzymes which catalyze protein phosphorylation at certain amino acids [...].
2.
Cicenas J, Meskinyte-Kausiliene E, Jukna V, Rimkus A, Simkus J, Soderholm D
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35625991
Serum- and glucocorticoid-regulated kinases (SGKs) are members of the AGC family of serine/threonine kinases, consisting of three isoforms: SGK1, SGK2, and SGK3. SGK1 was initially cloned as a gene transcriptionally...
3.
Zalyte E, Cicenas J
Int J Mol Med
. 2022 May;
49(6).
PMID: 35514314
Pancreatic cancer is a highly metastatic and therapy‑resistant disease. In the present study, the prospects of a novel approach to kill pancreatic cancer cells were examined: Starvation combined with ferroptosis...
4.
Cicenas J, Raciene A
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33668248
Cancers are a large group of diseases that mostly emerge because of the uncontrollable action of many different genes in human cells [...].
5.
Kuciauskas D, Dreize N, Ger M, Kaupinis A, Zemaitis K, Stankevicius V, et al.
Cancers (Basel)
. 2019 Jul;
11(7).
PMID: 31336714
Antitumor drug resistance remains a major challenge in cancer chemotherapy. Here we investigated the mechanism of acquired resistance to a novel anticancer agent RH1 designed to be activated in cancer...
6.
Rynkeviciene R, Simiene J, Strainiene E, Stankevicius V, Usinskiene J, Kaubriene E, et al.
Cancers (Basel)
. 2018 Dec;
11(1).
PMID: 30583549
Glioma is the most aggressive brain tumor of the central nervous system. The ability of glioma cells to migrate, rapidly diffuse and invade normal adjacent tissue, their sustained proliferation, and...
7.
Ger M, Kaupinis A, Petrulionis M, Kurlinkus B, Cicenas J, Sileikis A, et al.
Anticancer Res
. 2018 Oct;
38(10):5759-5765.
PMID: 30275197
Background/aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, particularly due to its aggressive course and challenging diagnostics in early-stage disease. The aim of this study...
8.
Cicenas J, Zalyte E, Bairoch A, Gaudet P
Cancers (Basel)
. 2018 Mar;
10(3).
PMID: 29494549
Protein kinases are a large family of enzymes catalyzing protein phosphorylation. The human genome contains 518 protein kinase genes, 478 of which belong to the classical protein kinase family and...
9.
Cicenas J, Zalyte E, Rimkus A, Dapkus D, Noreika R, Urbonavicius S
Cancers (Basel)
. 2017 Dec;
10(1).
PMID: 29267206
Mitogen-activated protein kinases (MAP kinases) are a family of kinases that regulates a range of biological processes implicated in the response to growth factors like latelet-derived growth factor (PDGF), epidermal...
10.
Gupta P, Bastikar V, Kuciauskas D, Kothari S, Cicenas J, Valius M
Med Oncol
. 2017 Sep;
34(10):176.
PMID: 28879492
Potential drug target identification and mechanism of action is an important step in drug discovery process, which can be achieved by biochemical methods, genetic interactions or computational conjectures. Sometimes more...